@ickihun I think you have missed the main point of the study, that "length of life" is not improved by moving from "OK" BG control to "great" BG control when using most drugs/insulin. Hence trying to push BG down to "normal" levels in Type2 with insulin is not a good option, better to accept a level that is a
little higher. (The ACCORD study showed the same.)
The study looks at 3 ranges of AC1 results, I expect they did not have enough data to look at more ranges. I don't have access to the full paper or dataset to see a graph of AC1 results in each range and
it is very unlikely that there is anything "magic" about 7%(53), I expect it was just a nice round number.
Below 7% (53), Between 7%(53) and 8.5%(69), And over 8%(69) People on insulin etc did best when they were between 7% and 8.5%, people on metformin 53
only did best when below 7%.
The NICE guidelines already have this, with the target AC1 being higher for people who are on more drugs or insulin.
We also have the issue that the study tells us
nothing about what happens when these drugs/insulin are combined with low carb....
There
may also be a
choice to be made between "length of life" and "not going blind" etc........ But I don't trust the research enough to know if this is the case.
Therefore
maybe you should reduce your insulin a little, to allow your BG to be a little higher, but it is possible the data is not strong enough to show your AC1 of 48 is too low. You could email the people who did the study to ask them what they think.
(PS remember that high insulin
increases inflammation, and I
think hypos had nothing to do with the results.)